Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.

Ruinuo JiaTanyou ShanAnping ZhengYaowen ZhangPing LuGuifang ZhangFeng WangZhiqiao XuGuobao ZhengDongxia TangWeiguo ZhangWanying LiRuonan LiYibo GuoLina LiuXiaoyong LuoYingjuan ZhengZhiwei ChangQi-Ming WangXinshuai WangXiaozhi YuanGuoqiang KongShuoguo LiRuina YangDan ZhouJing RenWeijiao YinJingxia LiJunqian ZhangZiqi WangManxi ShengBingyi XuLiuyan LiXiaoyi LiuZhihao LuLixin WanFuyou ZhouShegan Gao
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Capecitabine or XELOX did not significantly improve the 2-year OS rate over PF in DCRT for inoperable locally advanced ESCC. Capecitabine showed a lower incidence of grade ≥3 AEs than PF did.